TP53 and B-cell chronic lymphocytic leukemia: In addition, genetic mutations of regulatory genes, such as TP53 [18], NOTCH1 [19], and ATM [20], and aberrant expression of other microRNAs are associated with CLL pathogenesis, drug resistance development, and relapse [21].